Andree Blaukat

4.7k total citations · 1 hit paper
94 papers, 3.6k citations indexed

About

Andree Blaukat is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Andree Blaukat has authored 94 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Molecular Biology, 37 papers in Oncology and 14 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Andree Blaukat's work include DNA Repair Mechanisms (20 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Receptor Mechanisms and Signaling (13 papers). Andree Blaukat is often cited by papers focused on DNA Repair Mechanisms (20 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Receptor Mechanisms and Signaling (13 papers). Andree Blaukat collaborates with scholars based in Germany, United States and Italy. Andree Blaukat's co-authors include Ivan Đikić, Werner Müller‐Esterl, Stefan Offermanns, Sorin Tunaru, Klaus Pfeffer, Jukka Kero, Eva Grönroos, Frank T. Zenke, Friedhelm Bladt and Astrid Zimmermann and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Nature Medicine.

In The Last Decade

Andree Blaukat

93 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

2003 630 citations Sorin Tunaru, Andree Blaukat et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andree Blaukat Germany	31	2.1k	803	478	409	360	94	3.6k
Manjusri Das United States	29	2.4k 1.2×	1.2k 1.5×	381 0.8×	280 0.7×	319 0.9×	73	3.8k
Esther Zwick Germany	11	2.3k 1.1×	1.2k 1.5×	201 0.4×	415 1.0×	350 1.0×	12	3.7k
Mariona Graupera Spain	35	2.4k 1.1×	978 1.2×	603 1.3×	155 0.4×	493 1.4×	59	4.6k
Norbert Prenzel Germany	9	2.2k 1.0×	1.3k 1.6×	170 0.4×	373 0.9×	327 0.9×	9	3.6k
Shripad S. Bhagwat United States	22	2.1k 1.0×	611 0.8×	288 0.6×	290 0.7×	529 1.5×	53	4.0k
Ching-Shih Chen United States	46	3.3k 1.6×	920 1.1×	491 1.0×	165 0.4×	533 1.5×	83	5.3k
Pierre P. Roger Belgium	38	2.7k 1.3×	1.3k 1.6×	186 0.4×	300 0.7×	271 0.8×	104	4.8k
Gregory Hollis United States	36	2.7k 1.3×	1.0k 1.3×	561 1.2×	219 0.5×	996 2.8×	101	5.1k
Ainara Egia United States	22	4.0k 1.9×	1.0k 1.3×	262 0.5×	372 0.9×	352 1.0×	23	5.7k
Alexandre Arcaro Switzerland	31	2.6k 1.2×	659 0.8×	351 0.7×	123 0.3×	761 2.1×	51	3.9k

Countries citing papers authored by Andree Blaukat

Since Specialization

Citations

This map shows the geographic impact of Andree Blaukat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andree Blaukat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andree Blaukat more than expected).

Fields of papers citing papers by Andree Blaukat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andree Blaukat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andree Blaukat. The network helps show where Andree Blaukat may publish in the future.

Co-authorship network of co-authors of Andree Blaukat

This figure shows the co-authorship network connecting the top 25 collaborators of Andree Blaukat. A scholar is included among the top collaborators of Andree Blaukat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andree Blaukat. Andree Blaukat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Esdar, Christina, Nina Linde, Andreas Blum, et al.. (2025). M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer. Molecular Cancer Therapeutics. 24(7). 1040–1053. 1 indexed citations

Friese‐Hamim, Manja, Olga Bogatyrova, Felix Rohdich, et al.. (2023). Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models. Molecular Cancer Therapeutics. 23(2). 159–173. 1 indexed citations

Albers, Joachim, Manja Friese‐Hamim, Oliver Schadt, et al.. (2023). The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations. Molecular Cancer Therapeutics. 22(7). 833–843. 10 indexed citations

Turchick, Audrey, Astrid Zimmermann, Li-Ya Chiu, et al.. (2023). Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors. Molecular Cancer Therapeutics. 22(7). 859–872. 16 indexed citations

Zimmermann, Astrid, Frank T. Zenke, Li-Ya Chiu, et al.. (2022). A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies. Molecular Cancer Therapeutics. 21(6). 859–870. 32 indexed citations

Haines, Eric, Yuki Nishida, Weiguo Zhang, et al.. (2021). DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia. Scientific Reports. 11(1). 12148–12148. 23 indexed citations

Zenke, Frank T., Astrid Zimmermann, Christian Sirrenberg, et al.. (2020). Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models. Molecular Cancer Therapeutics. 19(5). 1091–1101. 118 indexed citations

Bensimon, Ariel, Paola Francica, Andree Blaukat, et al.. (2020). Deciphering MET‐dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics. Molecular Oncology. 14(6). 1185–1206. 9 indexed citations

Peters, Sheila Annie, Carl Petersson, Andree Blaukat, Joern-Peter Halle, & Hugues Dolgos. (2020). Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies. Drug Discovery Today. 25(5). 909–919. 12 indexed citations

10.

Zimmermann, Astrid, et al.. (2020). DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia. Frontiers in Oncology. 10. 127–127. 24 indexed citations

11.

Sun, Qing, Xiaohong Liu, Frank Czauderna, et al.. (2019). Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814. Molecular Cancer Research. 17(12). 2457–2468. 57 indexed citations

12.

Francica, Paola, Lluís Nisa, Daniel M. Aebersold, et al.. (2016). Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage–Induced Senescence Program in Gastric Cancer. Clinical Cancer Research. 22(21). 5322–5336. 27 indexed citations

13.

Medová, Michaela, Lluís Nisa, Paola Francica, et al.. (2015). Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition–Associated Checkpoint Abrogation. Molecular Cancer Research. 13(12). 1544–1553. 8 indexed citations

14.

Bladt, Friedhelm, Manja Friese‐Hamim, Christine Knuehl, et al.. (2013). EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors. Clinical Cancer Research. 19(11). 2941–2951. 114 indexed citations

15.

Medová, Michaela, Bruno Streit, Paola Francica, et al.. (2013). The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants. Molecular Cancer Therapeutics. 12(11). 2415–2424. 25 indexed citations

16.

Schermer, Bernhard, Katja Höpker, Heymut Omran, et al.. (2005). Phosphorylation by casein kinase 2 induces PACS‐1 binding of nephrocystin and targeting to cilia. The EMBO Journal. 24(24). 4415–4424. 68 indexed citations

17.

Micke, Patrick, Maryam Basrai, Andreas Faldum, et al.. (2003). Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications.. PubMed. 9(1). 188–94. 124 indexed citations

18.

Blaukat, Andree, et al.. (2003). Regulated and constitutive activation of specific signalling pathways by the human S1P₅ receptor. British Journal of Pharmacology. 138(3). 481–493. 27 indexed citations

19.

Tunaru, Sorin, et al.. (2003). Comparative Analysis of Functional Assays for Characterization of Agonist Ligands at G Protein–Coupled Receptors. SLAS DISCOVERY. 8(5). 500–510. 26 indexed citations

20.

Quitterer, Ursula, Christian Schröder, Andree Blaukat, et al.. (1996). On the structure of the amino-terminal domain ED1 of the B2 receptor. Immunopharmacology. 35(1). 23–26. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact